AI Agents Are Coming to the Pathology Lab, but the Evidence Is Not There Yet

Artificial intelligence has already transformed the way pathologists examine tissue. Whole-slide imaging turned glass slides into gigapixel digital files, and deep learning models learned to spot tumors, grade cancers, and quantify biomarkers with remarkable accuracy. Yet a new review published in the Journal of Translational Medicine argues that the next wave of pathology AI, so-called agentic systems that can plan, reason, and act autonomously, remains technically promising but clinically unproven. The paper, led by Xinyu Lu of Shanghai Eastern Hepatobiliary Surgery Hospital and Susu Luo, who holds appointments at the same hospital and at Moores Cancer Center at the University of California San Diego, offers one of the first systematic assessments of whether these autonomous AI architectures are ready for the diagnostic bench, and its answer is a carefully qualified no.

To understand why the review matters, it helps to grasp what makes an AI system agentic in the first place. Most pathology AI deployed today is a fixed pipeline: an image goes in, a prediction comes out, and the model has no ability to change its own behavior at inference time. Agentic systems break that mold. They coordinate multiple components, including perception models that analyze images, large language models that reason over textual knowledge, external tools such as databases or specialized classifiers, and feedback loops that let the system revise its own intermediate conclusions. Crucially, the control flow is dynamic rather than predetermined. The system decides, moment by moment, which tool to call, which region of a slide to examine next, and when it has gathered enough evidence to render a judgment.

The authors organize this emerging field with an operational taxonomy built on three pillars: dynamic control flow, inference-time tool selection, and knowledge integration. This framework matters because the term agentic has become a marketing buzzword as much as a technical one, applied to everything from simple chatbot wrappers to genuinely autonomous multi-model pipelines. By defining agency in terms of what a system actually does at inference time, whether it selects its own tools, integrates new knowledge on the fly, and adapts its reasoning path, the review gives researchers and regulators a common vocabulary for evaluating claims. Under this taxonomy, the authors survey architectures and enabling technologies across the major application domains of computational pathology: diagnosis, prognosis, and therapeutic support.

The technical appeal of agentic designs is easy to see. A single static model trained to detect one cancer type in one organ struggles the moment it encounters an unusual case, a rare variant, or a question it was never trained to answer. An agentic system, in principle, could recognize the limits of its own competence, consult a reference knowledge base, dispatch a specialized sub-model for a second opinion, and synthesize the results into a coherent report, much as a pathologist might consult a colleague or the literature. Early prototypes demonstrate that this kind of flexible orchestration is feasible, and the review treats that feasibility as established. The perception components, the language models, and the orchestration layers all exist and can be wired together into functioning systems.

Feasibility, however, is where the good news ends, at least for now. The review’s central and most consequential finding is that agentic architectures have not yet demonstrated clinical benefit. The evidence base consists almost entirely of retrospective benchmarks and research prototypes, studies in which systems are tested on archived data rather than deployed in live diagnostic workflows. Retrospective performance, the authors emphasize, is a notoriously poor predictor of real-world clinical value. A model that achieves impressive accuracy on a curated test set may fail in unpredictable ways when confronted with the staining variability, scanning artifacts, and case mix of an actual hospital.

There is a deeper methodological problem lurking in the literature, and the review names it directly: reported gains are difficult to attribute to agentic organization itself. When a new agentic system outperforms an older one, is the improvement due to the clever orchestration, or simply to a stronger underlying vision model, more training data, or a larger inference budget that lets the system think longer? Because studies differ in backbone models, datasets, and computational resources, most published comparisons cannot isolate the contribution of agency. This is a familiar trap in AI research, where architectural novelty often gets credit for gains that actually come from scale. Until head-to-head comparisons are run with matched backbones, matched data, and matched compute, the field cannot honestly claim that agentic organization, as opposed to brute capability, is what delivers the benefit.

The review also catalogues the specific risks that agentic designs introduce on top of those inherent in any medical AI. Large language models can hallucinate, generating confident but false statements, and in a pathology context a hallucinated finding woven into a diagnostic report is a patient-safety hazard. Multi-component systems expand the attack surface for security threats, since each tool call and knowledge lookup is a potential point of failure or manipulation. Computational cost is another practical concern: agentic systems that invoke multiple models and iterative reasoning loops consume far more compute than a single forward pass through a classifier, which affects both latency and the economics of deployment. And workflow integration remains the perennial stumbling block for pathology AI, because a system that is accurate but awkward to use, or that disrupts how pathologists actually work, will simply go unused.

Regulatory and human factors add further layers of complexity. Dynamic systems whose behavior depends on inference-time decisions are harder to validate and lock down than fixed models, raising unresolved questions about how regulators should assess software that does not always do the same thing given the same input. The authors also point to patient preferences as a consideration that is often absent from technical papers but central to clinical adoption, alongside the non-negotiable requirement that pathologists retain meaningful oversight of any AI-assisted diagnosis. Notably, the review does not treat agentic AI as inevitable. It explicitly identifies conditions under which specialist non-agentic models remain preferable, a stance that cuts against the industry narrative that autonomy is always the goal. For a well-defined task such as detecting mitotic figures or grading a common tumor subtype, a narrow, validated, inexpensive model may simply be the better tool.

So what would it take for agentic pathology AI to earn clinical trust? The authors lay out a translation roadmap that reads as a checklist for the field. First, prioritize verifiable tasks, meaning applications where the correctness of the AI’s output can be objectively checked, rather than open-ended reasoning with no ground truth. Second, run matched comparisons that isolate the effect of agentic organization from confounds like model scale. Third, pursue prospective and external validation, testing systems on new cases, at new institutions, in real time, rather than re-splitting old datasets. Fourth, establish lifecycle governance, continuous monitoring and updating frameworks appropriate to systems that may behave differently over time as their components evolve. Finally, design interfaces that preserve pathologist oversight, keeping the human diagnostician in command rather than relegating them to rubber-stamping machine output.

The timing of this sober assessment is significant. Agentic AI is arguably the hottest concept in the technology sector, and medicine is under intense pressure to adopt it, with vendors promising autonomous diagnostic agents that could ease workforce shortages and accelerate care. This review, published open access and grounded in a systematic survey rather than promotional claims, offers a counterweight: a technically literate account that concedes the engineering achievements while insisting that the clinical evidence simply does not exist yet. For pathologists, hospital administrators, and regulators, the message is to distinguish enthusiasm from evidence. For researchers, it is a call to design the rigorous studies that could eventually justify deployment. Agentic systems may well reshape computational pathology, but as this analysis makes clear, the road from impressive demo to dependable diagnosis runs through prospective trials, honest comparisons, and governance structures that keep patients, and the pathologists who serve them, firmly in the loop.

Subject of Research: Agentic AI architectures for computational pathology and their translational challenges

Article Title: Agentic systems in computational pathology: architectures, evidence, and translational challenges

Article References: Lu, X., Li, Q., Gao, Y., Dong, W., Lyu, M., Ma, S., Li, J., Wu, Y., Cai, L., Zhang, T., Lyu, S., Liu, Z., Liu, H., & Luo, S. (2026). Agentic systems in computational pathology: architectures, evidence, and translational challenges. Journal of Translational Medicine, 24(1), Article 1111. https://doi.org/10.1186/s12967-026-08829-0

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08829-0

Keywords: agentic AI, computational pathology, digital pathology, whole-slide imaging, large language models, clinical validation, translational medicine, AI regulation, hallucination risk, diagnostic AI, prospective validation, pathologist oversight